Intersect Capital’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Intersect Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-10,278	Closed	-$516K	–	107
2016 Q2	$516K	Hold	10,278	–	–	0.31%	62
2016 Q1	$550K	Buy	10,278 +4,570	+80%	+$268K	0.35%	58
2015 Q4	$375K	Hold	5,708	–	–	0.32%	64
2015 Q3	$322K	Hold	5,708	–	–	0.3%	69
2015 Q2	$337K	Hold	5,708	–	–	0.29%	63
2015 Q1	$345K	Sell	5,708 -466	-8%	-$27.1K	0.27%	62
2014 Q4	$355K	Buy	+6,174	New	+$344K	0.3%	58

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Intersect Capital's TEVA Position: Q3 2016 in Review

Intersect Capital sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2016, closing a stake of 10,278 shares — an estimated $516K sold.

Intersect Capital first reported a position in TEVA in Q4 2014 and held it in 7 quarters. The position peaked at $550K in Q1 2016. 798 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

Intersect Capital reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2016 after selling out during the quarter.
Intersect Capital sold 10,278 Teva Pharmaceutical Industries Limited shares in Q3 2016, an estimated $516K.
Intersect Capital first reported a position in Teva Pharmaceutical Industries Limited in Q4 2014 and held it in 7 quarters.
Intersect Capital's Teva Pharmaceutical Industries Limited position peaked at $550K in Q1 2016.
798 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2016.

Based on Intersect Capital's 13F filing for Q3 2016, filed 27 Oct 2016.